Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > U.S. COPD Market - Therapeutic Overview and Patient Outlook
Category
Pharmaceutical (4988)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (561)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

U.S. COPD Market - Therapeutic Overview and Patient Outlook

Published by Frost & Sullivan
Published June, 2007 Product code 52899
Content info 80 Pages
Price
US $ 6000 Web Access (Regional License)
US $ 6500 Hard Copy & Web Access (Regional License)


U.S. COPD Market - Therapeutic Overview and Patient Outlook published by Frost & Sullivan in June, 2007. This report consists of 80 Pages and the price starts from US $ 6000.

Introduction

Abstract

This research service covers the U.S. COPD market from 2003-2013. Included are patient forecasts and a therapeutic overview. The market is segmented by product class: bronchodilators, anti-inflammatories, combination therapies, and novel therapeutic approaches. The novel therapeutic approaches segment covers selected products in the pipeline that are outside current marketed segments. Major market challenges, drivers, restraints, and strategic recommendations to overcome market challenges are also discussed.

Table of Contents

1 EXECUTIVE SUMMARY

  • Executive Summary
    • Introduction

2 TOTAL MARKET

  • Research Scope and Methodology
    • Scope and Segmentation
    • Research Methodology
  • Disease Overview
    • Introduction
    • Disease Definition
    • Symptoms
    • Risk Factors
    • Diagnosis
    • Treatments
    • Drug Delivery Methods
    • Disease Statistics
    • Competitive Structure
  • Patient Outlook
    • Patient Forecasts
  • General Market Trends
    • Challenges
    • Strategic Recommendations for Challenges
    • Market Drivers
    • Market Restraints

3 MARKETED THERAPIES OVERVIEW

  • Overview
    • Bronchodilators
    • Anti-inflammatories
    • Combination Therapies
    • Novel Therapeutic Approaches

4 APPENDIX

  • Decision Support Databases
    • Chronic Obstructive Pulmonary Disease Population
    • Prevalence of Male Smokers
    • Prevalence of Female Smokers
    • Population 65 and Over
    • Prevalence of Asthma
Back to Top